Transplacental passage of nirmatrelvir in pregnant women with <scp>COVID</scp>‐19-Reference-Cited by-同舟云学术

Transplacental passage of nirmatrelvir in pregnant women with COVID‐19

Published:2023-09-23 Issue:1 Volume:164 Page:351-353
ISSN:0020-7292
Container-title:International Journal of Gynecology & Obstetrics
language:en
Short-container-title:Intl J Gynecology & Obste

Author:

Chuang Ming‐Ta¹,Su Mei‐Tsz¹,Chou Chen‐Hsi²,Liang Yu‐Ling¹,Tsai Hsing‐Fen¹,Yu Pei‐Hsiu¹,Wu Meng‐Hsing¹,Ko Wen‐Chien³,Tsai Pei‐Yin¹

Affiliation:

1. Department of Obstetrics and Gynecology National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan

2. Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine National Cheng Kung University Tainan Taiwan

3. Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan

Abstract

SynopsisThe transplacental passage of nirmatrelvir in pregnant women with COVID‐19 is limited and reinforces the safety of using Paxlovid in pregnancy.

Funder

National Cheng Kung University Hospital

Publisher

Wiley

Subject

Obstetrics and Gynecology,General Medicine

Link

https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1002/ijgo.15147

Reference8 articles.

1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

2. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis

3. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

4. Differences in cytochrome p450 enzyme expression and activity in fetal and adult tissues

5. European Medicines Agency. Accessed Augusr 30 2023.https://www.ema.europa.eu/en/documents/assessment‐report/paxlovid‐epar‐public‐assessment‐report_en.pdf

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 therapeutics for the pregnant patient;Seminars in Perinatology;2024-06

2. The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats;npj Viruses;2024-01-24